Reata closes secured term loan financing for up to USD 275 million
16. Mai 2023 – On 12 May 2023, Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a global pharmaceutical company primarily focused on investigating experimental oral antioxidative and anti-inflammatory drugs, closed a secured term loan financing for up to USD 275 million from funds managed by Pharmakon Advisors, LP, a leading investor in non-dilutive debt for the life sciences industry and the investment manager of the BioPharma Credit funds.
Walder Wyss team advised the funds managed by Pharmakon Advisors, LP. The team was led by Tervel Stoyanov (Counsel, Banking & Finance) and included Maurus Winzap (Partner, Tax) and Ursina Gremminger (Managing Associate, Tax).